Clinical Trials Arena on MSN4d
NiKang concludes first cohort dosing in Phase I trial of NKT3964 for tumours
NiKang Therapeutics has concluded the first cohort dosing in the open-label Phase I trial of NKT3964 as a monotherapy for ...
Hosted on MSN28d
Scientists propose CDK2 enzyme as new target for cancer therapy
An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic resistance to common breast cancer drugs—including a class of targeted ...
Nature4y
The classical and minimal models of cell cycle control
(B) CDK1 and CDK2 bind to multiple cyclins (cyclin types A, B, D and E), whereas CDK4 and CDK6 only partner D-type cyclins. Thick lines represent the preferred pairing for each kinase. (C ...
Medical Xpress29d
Scientists propose CDK2 enzyme as new target for cancer therapy
Cyclin-dependent kinase 2 (CDK2) is identified as a potential target for cancer therapy, particularly in overcoming resistance to CDK4/6 inhibitors used in treating hormone receptor-positive ...